Prevention of cerebrovascular and cardiovascular Events of ischaemic origin with teRutroban in patients with a history oF ischaemic strOke or tRansient ischaeMic attack
ISRCTN | ISRCTN66157730 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN66157730 |
EudraCT/CTIS number | 2005-003700-10 |
Secondary identifying numbers | CL3-18886-012 |
- Submission date
- 22/03/2006
- Registration date
- 13/06/2006
- Last edited
- 25/01/2018
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration and not expected to be available in the future
Contact information
Prof Marie-Germaine Bousser
Scientific
Scientific
Hopital Lariboisiere
Service de Neurologie
2 Rue Ambroise Pare
Paris
75010
France
Study information
Study design | Randomized double-blind parallel-group study |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised parallel trial |
Study setting(s) | Not specified |
Study type | Treatment |
Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
Scientific title | Prevention of cerebrovascular and cardiovascular Events of ischaemic origin with teRutroban in patients with a history oF ischaemic strOke or tRansient ischaeMic attack |
Study acronym | PERFORM |
Study objectives | To demonstrate the superiority of terutroban over a marketed drug (antithrombotic agent) in reducing the number of cerebrovascular and cardiovascular events in patients with cerebrovascular diseases |
Ethics approval(s) | First Ethics Committee approval in Italia on 06/12/2005, reference number: 42 |
Health condition(s) or problem(s) studied | Ischaemic stroke |
Intervention | S 18886 (terutroban) versus antithrombotic agent |
Intervention type | Drug |
Pharmaceutical study type(s) | |
Phase | Not Applicable |
Drug / device / biological / vaccine name(s) | Terutroban |
Primary outcome measure | Cerebrovascular and cardiovascular events |
Secondary outcome measures | Safety criteria |
Overall study start date | 22/02/2006 |
Completion date | 31/03/2010 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Adult |
Sex | Both |
Target number of participants | 18000 |
Key inclusion criteria | Male or female aged at least 55 years with recent history of stroke or transient ischaemic attack |
Key exclusion criteria | Haemorrhagic stroke |
Date of first enrolment | 22/02/2006 |
Date of final enrolment | 31/03/2010 |
Locations
Countries of recruitment
- Austria
- Belgium
- Bulgaria
- Canada
- Chile
- China
- Croatia
- Czech Republic
- Finland
- France
- Greece
- Hong Kong
- India
- Ireland
- Korea, South
- Lithuania
- Mexico
- Morocco
- Netherlands
- New Zealand
- Norway
- Portugal
- Romania
- Singapore
- Slovenia
- Sweden
- Taiwan
- Tunisia
- Ukraine
Study participating centre
Hopital Lariboisiere
Paris
75010
France
75010
France
Sponsor information
Institut de Recherches Internationales Servier (France)
Industry
Industry
50 rue Carnot
Suresnes
92284
France
Website | http://www.servier.com/ |
---|---|
https://ror.org/034e7c066 |
Funders
Funder type
Industry
Institut de Recherches Internationales Servier (France)
No information available
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | Yes |
IPD sharing plan summary | Available on request |
Publication and dissemination plan | Publication plan: All phases - Interventional studies ending before 01/10/2018: Summary results will be published on https://clinicaltrials.servier.com/ within 12 months after the end of the study. All phases - Interventional studies ending after 01/10/2018: Summary results and a lay summary will be published on https://clinicaltrials.servier.com/ within 12 months after the end of the study. Phase 3 only - The results will be published in scientific literature within 18 months after the end of the study. |
IPD sharing plan | The datasets generated during and/or analysed during the current study will be available upon request from https://clinicaltrials.servier.com/ if a Marketing Authorisation has been granted after 2014. |
Study outputs
Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
---|---|---|---|---|---|
Basic results | No | No | |||
Results article | results | 11/06/2011 | Yes | No | |
Results article | results | 01/08/2014 | Yes | No | |
Results article | results | 01/04/2016 | Yes | No | |
Results article | results | 01/04/2017 | Yes | No |
Editorial Notes
25/01/2018: Publication plan and IPD sharing statement added.
14/12/2017: results summary added. Publication reference added.
18/03/2016: Publication reference added.